Treatment sequences in EGFR mutant advanced NSCLC

Area of Science:

• Oncology
• Genomics
• Pharmacology

Background:

• Common Epidermal Growth Factor Receptor (EGFR) gene mutations, including exon 19 deletion and L858R in exon 21, are primary actionable genomic alterations in non-small cell lung cancer (NSCLC).
• Third-generation EGFR tyrosine kinase inhibitors (TKIs) represent a new standard in first-line treatment for advanced NSCLC, significantly altering disease progression and survival rates.

Purpose of the Study:

• To review current and emerging therapeutic strategies for advanced NSCLC with common EGFR mutations.
• To discuss methods for overcoming resistance mechanisms and managing residual disease.
• To propose a management algorithm for clinicians, integrating clinical and biological parameters.

Main Methods:

• Review of published and forthcoming advances in NSCLC treatment.
• Analysis of therapeutic strategies targeting EGFR mutations and resistance pathways.
• Development of a clinical decision-making algorithm.

Main Results:

• EGFR TKIs have improved survival, but resistance and heterogeneity limit long-term outcomes.
• Combination therapies show promise for progression-free survival but may increase side effects.
• Diverse therapeutic sequences are emerging for advanced NSCLC with EGFR mutations.

Conclusions:

• New treatment options offer potential for improved outcomes in advanced NSCLC with EGFR mutations.
• Further understanding of the impact on survival and quality of life is needed.
• A personalized management approach considering clinical and biological factors is crucial.